All In MedTech

Device Trial Radar · NCT07548164

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Alternative Boost Approaches in Radiation Therapy IRreversible Electroporation Versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer (IRRADIANT)

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Apr 16, 2029

Study completion Apr 16, 2029

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Angiodynamics, Inc.
First posted
Apr 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).

Conditions

  • Prostate Cancer

Interventions

  • NanoKnife SystemDevice

    The NanoKnife System is the device that is used for Irreversible Electroporation/IRE. The NanoKnife Generator is a microprocessor-controlled low energy direct current (LEDC) irreversible electroporation device.

  • Stereotactic Body Radiation TherapyRadiation

    Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biopsy negative rate at 2 yearsTime frame: 2 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)

    Montvale, New Jersey · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.